Portal de Periódicos da CAPES

COVID‐19: What type of cytokine storm are we dealing with?

2020; Wiley; Volume: 93; Issue: 1 Linguagem: Inglês

10.1002/jmv.26317

1096-9071

Guillaume Monneret, Ihsane Benlyamani, Morgane Gossez, Jesús F. Bermejo-Martín, Marta Martín-Fernández, Pierre Sesques, Florent Wallet, Fabienne Venet,

Inflammasome and immune disorders

Journal of Medical VirologyVolume 93, Issue 1 p. 197-198 LETTER TO THE EDITOR COVID-19: What type of cytokine storm are we dealing with? Guillaume Monneret, Corresponding Author Guillaume Monneret [email protected] orcid.org/0000-0002-9961-5739 EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France Correspondence Guillaume Monneret, Immunology Laboratory, Edouard Herriot Hospital, Hospices Civils de Lyon, Pavillon E-5 place d'Arsonval, 69437 Lyon, France. Email: [email protected]Search for more papers by this authorIhsane Benlyamani, Ihsane Benlyamani Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceSearch for more papers by this authorMorgane Gossez, Morgane Gossez EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceSearch for more papers by this authorJesus F Bermejo-Martin, Jesus F Bermejo-Martin Biomedical research Department, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain Biomedical research Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, SpainSearch for more papers by this authorMarta Martín-Fernandez, Marta Martín-Fernandez Biomedical research Department, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain Biomedical research Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, SpainSearch for more papers by this authorPierre Sesques, Pierre Sesques Medical Intensive Care Unit, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, FranceSearch for more papers by this authorFlorent Wallet, Florent Wallet Department of Hematology, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, FranceSearch for more papers by this authorFabienne Venet, Fabienne Venet EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceSearch for more papers by this author Guillaume Monneret, Corresponding Author Guillaume Monneret [email protected] orcid.org/0000-0002-9961-5739 EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France Correspondence Guillaume Monneret, Immunology Laboratory, Edouard Herriot Hospital, Hospices Civils de Lyon, Pavillon E-5 place d'Arsonval, 69437 Lyon, France. Email: [email protected]Search for more papers by this authorIhsane Benlyamani, Ihsane Benlyamani Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceSearch for more papers by this authorMorgane Gossez, Morgane Gossez EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceSearch for more papers by this authorJesus F Bermejo-Martin, Jesus F Bermejo-Martin Biomedical research Department, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain Biomedical research Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, SpainSearch for more papers by this authorMarta Martín-Fernandez, Marta Martín-Fernandez Biomedical research Department, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain Biomedical research Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, SpainSearch for more papers by this authorPierre Sesques, Pierre Sesques Medical Intensive Care Unit, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, FranceSearch for more papers by this authorFlorent Wallet, Florent Wallet Department of Hematology, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, FranceSearch for more papers by this authorFabienne Venet, Fabienne Venet EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, FranceSearch for more papers by this author First published: 18 July 2020 https://doi.org/10.1002/jmv.26317Citations: 13Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Andrianopoulos I, Papathanasiou A, Papathanakos G, Chaidos A, Koulouras V. Tocilizumab's efficacy in COVID-19 patients is determined by the presence of cytokine storm [published online ahead of print June 22, 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.26209 10.1002/jmv.26209 PubMedWeb of Science®Google Scholar 2Morena V, Milazzo L, Oreni L, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020; 76: 36-42. 10.1016/j.ejim.2020.05.011 CASPubMedWeb of Science®Google Scholar 3Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest. 2020; 158: e-15-e-19. 10.1016/j.chest.2020.04.024 CASPubMedWeb of Science®Google Scholar 4Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020; 8(5):695. 10.3390/microorganisms8050695 CASPubMedWeb of Science®Google Scholar 5Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020; 129:104444. 10.1016/j.jcv.2020.104444 CASPubMedWeb of Science®Google Scholar 6Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis [published online ahead of print April 28, 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.25948 10.1002/jmv.25948 Web of Science®Google Scholar 7Coutant DE, Hall SD. Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance. J Clin Pharmacol. 2018; 58(7): 849-863. 10.1002/jcph.1093 CASPubMedWeb of Science®Google Scholar 8Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016; 315(8): 801-810. 10.1001/jama.2016.0287 CASPubMedWeb of Science®Google Scholar 9Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003; 2(5): 391-405. 10.1038/nrd1084 CASPubMedWeb of Science®Google Scholar 10Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004; 32(11): 2173-2182. 10.1097/01.CCM.0000145229.59014.6C CASPubMedWeb of Science®Google Scholar 11Monneret G, Cour M, Viel S, Venet F, Argaud L. Coronavirus disease 2019 as a particular sepsis: a 2-week follow-up of standard immunological parameters in critically ill patients [published online ahead of print June 2, 2020]. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06123-1 10.1007/s00134-020-06123-1 PubMedWeb of Science®Google Scholar 12Jeannet R, Daix T, Formento R, Feuillard J, Francois B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression [published online ahead of print June 8, 2020]. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06127-x 10.1007/s00134-020-06127-x PubMedWeb of Science®Google Scholar Citing Literature Volume93, Issue1Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐VIIIJanuary 2021Pages 197-198 ReferencesRelatedInformation